Slide 1: Anaergia Inc. Q2 2022 Results - Investor Conference Call
Anaergia Inc. Q2 2022 Results - Investor Conference Call August 16, 2022 TSX: ANRG Fueling a Sustainable World
Slide 2: Disclaimers
Disclaimers Forward-Looking Information Certain statements in this presentation and certain oral statements made by senior management during the earnings conference call on August 16, 2022 (collectively, this "presentation") are “forward-looking information” within the meaning of applicable Canadian
Slide 3: Participating in Today's Call
Participating in Today’s Call 3
Slide 4: Key Highlights
Key Highlights Revenue Growth (C$ millions) Capital Sales in Calimera Bio Major Incentive Global Markets Commissioned Programs YTD Revenue Announced new capital sales contracts Two of six Italian BOOs now Inflation Reduction Act, REPowerEU, 40% for facilities in Canada, Japan, and commissioned, all
Slide 5: Revenue Backlog and Market Opportunities
Revenue Backlog and Market Opportunities • European gas commodity prices spike again. IEA projecting prices above 40 USD/MMBTU for the remainder of 2022, well above historical Q2 2022 CLOSING REVENUE Dutch TTF Natural Gas Price (Futures)2 average pricing through to 2025 BACKLOG1 • Italy extends the
Slide 6: Financial Summary
Financial Summary YTD 2022 Revenue By Geography 3% Restated Restated Q2 YTD NA (Millions CAD) Q2 Change YTD Change 2022 2022 2021 2021 37% EMEA 60% APAC Revenues 42.2 26.8 57% 77.8 55.4 40% Gross Profit 8.0 6.0 15.3 13.7 Gross Margin 18.9% 22.3% 19.7% 24.7% • Revenue throughout 2022 has grown substa
Slide 7: Recent Technical Accounting Changes
Recent Technical Accounting Changes This is a technical accounting matter only and does not impact the company’s ongoing operations, cash position, or future cash flows from BOO assets. Ultimate profitability is practically unchanged. • Following discussions with the Company’s external auditor, KPMG
Slide 8: Restatement of Financials
Restatement of Financials Previously Restated FY (Millions CAD) Reported FY Adjustment • Accounting changes eliminate some revenues that 2021 2021 were previously recognized as capital sales for 3 BOO projects in the US Revenues 153.6 (26.5) 127.0 • 2021 Adjustment impact of $26.5 M on revenues Gros
Slide 9: Capital Management and Liquidity
Capital Management and Liquidity • Cash, cash equivalents, and current restricted cash as of June 30, 2022 of $88.3 M, up by $11.6 M from $76.7 M at the end of Q1 2022. Non- current restricted cash of $14.3 M. • Cash used in investing activities (in US and Europe) during Q2 2022 reported at $50.6 M.
Slide 10: Business Development – Our Segments
Business Development – Our Segments As more BOO facilities become operational, the revenue make-up will shift towards the high-margin, recurring BOO revenue generated from tipping fees and RNG offtake sales. Capital Sales Proprietary Anaergia Waste-to-Energy • Sales of proprietary technology solutio
Slide 11: Capital Sales
Capital Sales Restated Restated CAD Million Q2 2022 Q2 2021 Change YTD 2022 YTD 2021 Change Capital Sales Revenues $34.5 $22.6 53% $64.4 $48.9 32% Significant Capital Sales Growth • Overall, YTD capital sales revenue up 32% YOY primarily due to revenue growth in Italy and execution on large projects
Slide 12: Services and BOO
Services and BOO Restated Restated CAD Million Q2 2022 Q2 2021 Change YTD 2022 YTD 2021 Change Services $4.8 $3.0 58% $8.4 $4.6 82% BOO $2.9 $1.2 147% $5.0 $1.9 161% Continued Service Revenue Growth • Service segment of the business continues to grow, with Q2 service revenue up 58% YOY • Large contr
Slide 13: BOO Overview
BOO Overview No. of Annual RNG Output1 Run-Rate Location Consolidated CAPEX2 BOO Revenue Projects (MMBTU) EBITDA3, 4 5 Backlog PROJECTS BACKLOG BOOs in North America5 6 2,073,000 ~$315 M ~$81 M Current $4.4B Operation6 Q2 2021 $2.5B Europe5 7 2,166,000 ~$367 M ~$96 M Change +76% 8 BOOs in Execution
Slide 14: Calimera-Bio
Calimera-Bio The second of 6 Italian BOO facilities to start operations in 2022 ~92,000 MMBTU/YR of RNG 30,000 Tonnes/YR of Waste Diverted C$30M Consolidated Capex C$6M Expected Run-Rate EBITDA1 (1) "Run-Rate EBITDA" is a non-IFRS measure. Please refer to "Non-IFRS Measures" in our management’s disc
Slide 15: Key Q2 Takeaways
Key Q2 Takeaways Revenue acceleration was demonstrated in Q2 and is expected to continue in each of the following quarters. The overall business fundamentals remain strong, and the business has seen healthy growth, as evidenced by a 57% YOY increase in Q2 revenues. The company has 13 BOO facilitie
Slide 16: Q&A
Q&A 16
Slide 17: Thank you for attending.
Thank you for attending. 17